An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
OriV508, developed by Union Hospital and OriCell Therapeutics, targets relapsed/refractory hematological malignancies, specifically multiple myeloma and aggressive B-cell non-Hodgkin lymphoma. The market for CAR-T therapies is rapidly expanding, with significant competition from established players like Novartis and Gilead. Successful outcomes in this trial could position OriV508 as a viable treatment option, potentially capturing market share in a high-demand segment. The trial's single-arm design and focus on safety and preliminary efficacy will be critical for attracting investment and partnership opportunities, especially given the stringent eligibility criteria that may limit patient enrollment.
Indication: Multiple Myeloma (MM)
Modality: cell therapy
Target: BCMA/CD19 dual-target CAR
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCMA/CD19 dual-target CAR
View original source fields
Condition raw: Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)
Condition normalized: Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: BCMA/CD19 dual-target CAR
Target normalized: BCMA/CD19 dual-target CAR